Abstract
Factors Impacting Progression-Free Survival after CD19-Specific CAR-T Cell Therapy for Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have